Status:
UNKNOWN
Early Detection of Cardiac Damage With CMR in Women With Breast Cancer
Lead Sponsor:
Radboud University Medical Center
Conditions:
Cardiotoxicity
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemothe...
Eligibility Criteria
Inclusion
- Female
- Age ≥ 18 years
- A diagnosis of primary breast cancer
- Starting (neo-) adjuvant chemotherapy treatment within 2 months after screening
- Cardiotoxicity risk score of intermediate, high or very high risk
Exclusion
- Previous radiotherapy or systemic cancer treatment
- Cancer metastasis
- Life expectancy of less than 6 months
- History of myocardial infarction or heart failure
- Known contra-indications for CMR
- Refusal or inability to provide informed consent
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2021
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04046315
Start Date
March 1 2020
End Date
March 31 2021
Last Update
March 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Medical Center
Nijmegen, Netherlands, 6500 HB